Ranbaxy First to Offer Tablet and Suspension Forms of Anti-Infective Agent
ePT--the Electronic Newsletter of Pharmaceutical Technology
Ranbaxy received full market approval from the US Food and Drug Admnistration for its anti-infective agent ?Clarithromycin? oral suspension.
Haryana, India (Oct. 2)-Ranbaxy received full market approval from the US Food and Drug Admnistration for its anti-infective agent “Clarithromycin” oral suspension, USP (125 mg/5 mL and 250 mg/5 mL). The approval makes the company the first to win generic approval for the oral suspension form and the tablet form.
FDA’s Office of Generic Drugs determined the Ranbaxy’s formulation was bioequivalent and offers the same therapeutic effect as that of the reference listed drug “Biaxin” granules of Abbott Laboratories.
Total annual market sales for Clarithromycin were $99.7 million, with suspension sales totaling $25.3 million.
PacBio Chosen as Tech Partner for Global Alzheimer’s Disease Research Project
April 23rd 2025The project, the North African Dementia Registry, will unite multiple entities for the purpose of developing a comprehensive dataset to advance the research community’s understanding of Alzheimer’s disease and other dementias in diverse populations.
